Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(80.0%)

N/A

1(20.0%)

5Total

Phase 1(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05155267Recruiting

Biomonitoring of Internal Exposure to MNPLs, and Its Effects, in Blood of Patients With Chronic Kidney Disease (CKD)

Role: collaborator

NCT05910489Not Yet Recruiting

Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect

Role: collaborator

NCT04113876Completed

Circadian Health and Influential Factors

Role: collaborator

NCT03720184Not ApplicableCompleted

Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass

Role: collaborator

NCT02566655Phase 1Completed

Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis

Role: collaborator

NCT04505709Unknown

Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19

Role: collaborator

NCT02280135Phase 1Completed

Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa

Role: collaborator

NCT02286011Phase 1Unknown

Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis

Role: collaborator

NCT02566681Phase 1Unknown

Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis

Role: collaborator

All 9 trials loaded